Neumora Therapeutics Inc. Common Stock

NMRA | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.69

-$0.04 (-5.48%)

At close: Sep 21, 2026, 4:00 PM ET

$0.72

+$0.03 (+4.32%)

After-hours: Sep 21, 2026, 7:55 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-5.48%

(1D)

Rating

Updated: Aug 10, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $128.18M

1D Range

0.68 0.73

52W Range

0.68 3.65

Valuation (TTM)

PE -0.56

PB 2.88

EV/EBITDA -0.06

Valuation (NTM)

Forward PE N/A

Forward PEG 0.02

Price Target $4.50

Cash Flow

FCF Yield -140.8%

SBC Adj. FCF Yield -162.7%

SBC Impact -15.5%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 16.6% | 3.4%

FCF 3Y | 5Y 4.7% | -14.0%

Returns

ROA -169.9%

ROE -242.3%

ROIC -216.1%

Financial Health

Net Cash

$116.49M

Current Ratio 4.50

Interest Coverage -32.71

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerat...

Sector Healthcare

Industry Biotechnology

Employees 63

IPO Date Sep 14, 2023

Website www.neumoratx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$4.50

Upside

+552.17%

Buy (6)

Hold (1)

Sell (0)

Analyst Details ➞